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Urinary tract infections (UTIs) are among the most widespread microbial diseases
and their economic impact on the society is substantial. The continuing increase of
antibiotic resistance worldwide is worrying. As a consequence, well-tolerated, highly
effective therapeutic alternatives are without delay needed. Although it has been
demonstrated that bacteriophage therapy may be effective and safe for treating UTIs,
the number of studied patients is low and there is a lack of randomized controlled
trials (RCTs). The present study has been designed as a two-phase prospective
investigation: (1) bacteriophage adaptation, (2) treatment with the commercially available
but adapted Pyo bacteriophage. The aim was to evaluate feasibility, tolerability, safety,
and clinical/microbiological outcomes in a case series as a pilot for a double-blind
RCT. In the first phase, patients planned for transurethral resection of the prostate
were screened (n = 130) for UTIs and enrolled (n = 118) in the study when the
titer of predefined uropathogens (Staphylococcus aureus, E. coli, Streptococcus spp.,
Pseudomonas aeruginosa, Proteus mirabilis) in the urine culture was ≥104 colony
forming units/mL. In vitro analysis showed a sensitivity for uropathogenic bacteria
to Pyo bacteriophage of 41% (48/118) and adaptation cycles of Pyo bacteriophage
enhanced its sensitivity to 75% (88/118). In the second phase, nine patients were treated
with adapted Pyo bacteriophage and bacteria titer decreased (between 1 and 5 log)
in six of the nine patients (67%). No bacteriophage-associated adverse events have
been detected. The findings of our prospective two-phase study suggest that adapted
bacteriophage therapy might be effective and safe for treating UTIs. Thus, well-designed
RCTs are highly warranted to further define the role of this potentially revolutionizing
treatment option.
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INTRODUCTION
Emergence and re-emergence of multiple antibiotic resistant bacterial infections and their rapid
spread in the environment has led to a new rise of scientific interest toward bacteriophage therapy
as an alternative to antibiotics. Use of bacteriophages for treatment of bacterial infections has
been suggested by the French-Canadian scientist Felix d’Herelle in 1917. Since then, bacteriophage
therapy has been applied in different fields of medicine, for treatment of various bacterial infections
(Chanishvili, 2012). However, after the discovery of penicillin in 1940s the Western scientific
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societies gave the preference to antibiotic therapy, while many
physicians and researchers in the former Soviet Union republics
remained dedicated to bacteriophage therapy and continued to
use it alone or in combination with antibiotics (Chanishvili,
2012), see also Supplementary Material for more references,
partly in Russian.
Lower urinary tract symptoms (LUTS) are a common problem
in adult men with a high impact on quality of life (Martin
et al., 2011). Traditionally LUTS have been related to bladder
outlet obstruction, which is often caused by prostatic enlargement
(Abrams et al., 2002). Prostatic enlargement occurs in about
25% of all men in their fifties, 30% in their sixties, and in
50% of men aged 80 years or older (Kupelian et al., 2006).
Transurethral resection of prostate (TURP) is regarded the
cornerstone of surgical treatment of LUTS secondary to benign
prostatic obstruction (Cornu et al., 2015). These patients have a
relevant risk for urinary tract infections (UTIs) (Schneidewind
et al., 2017). Beside the possible development of residual urine,
which acts as a growth medium for bacteria (Truzzi et al.,
2008), many of these patients rely on a short or long-term
catheterization prior to further treatment. Single insertion of
a catheter causes infection in 1–2% of cases, while catheters
with open-drainage systems result in bacteriuria in almost 100%
of the cases within 3–4 days (Warren, 1992; Bonkat et al.,
2018).
Therefore, we decided to combine TURP with bacteriophage
therapy, using bacteriophages as a replacement of perioperative
antibiotics. The present study has been designed as prospective
two-phase (first phase: bacteriophage adaptation, second
phase: treatment with the commercially available but adapted
Pyo bacteriophage) study preceding a randomized, placebo-
controlled, double-blind clinical trial (Leitner et al., 2017) to
assess efficacy and safety of adapted bacteriophages for treating
(catheter associated) UTIs (Nicolle et al., 2005; Hooton et al.,
2010; Bonkat et al., 2018) in patients undergoing TURP.
PATIENTS AND METHODS
Ethics Committee Approval
This prospective two-phase study has been approved by
the local ethics committee (TNCU-02/283; Tbilisi, Georgia)
and was conducted at the Alexander Tsulukidze National
Center of Urology (TNCU), Tbilisi, Georgia and the Eliava
Institute of Bacteriophage, Microbiology and Virology (EIBMV),
Tbilisi, Georgia. The study was designed as an investigation
preceding the randomized controlled trial (RCT) registered at
ClinicalTrials.gov: NCT03140085 (Leitner et al., 2017).
Patients
From September 2016, 130 patients planned for TURP were
screened in preparation for the RCT (Leitner et al., 2017) at
the TNCU. In the first phase, urine cultures from all patients
(taken by mid-stream urine, or from the existing transurethral
or suprapubic catheter) were evaluated. Overall, 118 (91%) of
the 130 screened patients had positive urinary cultures with
predefined uropathogens (i.e., Staphylococcus aureus, E. coli,
Streptococcus spp., Pseudomonas aeruginosa, Proteus mirabilis)
and ≥104 colony forming units (CFU)/mL. The isolated cultures
were consecutively subjected to an in vitro bacteriophage
sensitivity test to the commercially available and in Georgia
registered Pyo bacteriophage solution (Eliava BioPreparations
Ltd., Tbilisi, Georgia), which underwent adaptation cycles, as
described in the next paragraph. In the second phase, nine
patients who had scored sensitive to the cocktail were further
subjected to bacteriophage treatment in a non-blinded fashion.
Exclusion criteria were symptomatic UTIs, microorganisms
not sensitive to Pyo bacteriophage and age under 18 years.
From all patients, prostate size, prostate specific antigen (PSA),
International Prostate Symptom Score (IPSS) questionnaire
(Barry et al., 1992) values, maximum flow rate and post void
residual were collected prior to surgery. Resected prostate volume
was collected and histological results were determined. Urine
culture sampling was repeated 7 days after surgery or at the time
of any adverse events. Written informed consent was obtained
from all included patients.
Bacteriophage Preparation and
Adaptation
To cover a diversity of uropathogens a commercial preparation
called Pyo bacteriophage produced by Eliava BioPreparations
Ltd., Tbilisi, Georgia, was used for treating UTIs. This
bacteriophage cocktail is composed of bacteriophage
lines active against a broad spectrum of uropathogenic
bacteria: Staphylococcus aureus, E. coli, Streptococcus
spp. (including Streptococci group D renamed now to
Enterococcus spp.), Pseudomonas aeruginosa, and Proteus
spp. of urological infections (Chanishvili, 2012). As is common
practice, commercial bacteriophage cocktails, including Pyo
bacteriophage, are regularly adapted by the EIBMV with the aim
to increase the efficacy of the bacteriophage cocktail toward newly
emerging pathogens (Kutter et al., 2010; Villarroel et al., 2017;
McCallin et al., 2018). Also in our study we applied adaptation to
enhance the efficacy and coverage toward uropathogenic strains
that initially scored intermediate or resistant in the in vitro
sensitivity study, in a similar way as done in the previously
conducted in vitro study (Sybesma et al., 2016). The method is
based on Appelmans’ protocol for titration of bacteriophages
(Appelmans, 1921) and selects for h-mutants with a broader
and stronger host–bacteriophage interaction (Merabishvili et al.,
2018). Similar as for the determination of the minimal inhibitory
concentration for antibiotics (Levison and Levison, 2009),
Appelmans’ method is based on liquid titration of bacteriophages
and determines the lowest concentration of bacteriophages that
show optical transparency over 24–72 h in a suspension with pre-
selected bacterial strains resistant to the bacteriophage cocktail.
This dilution with the lowest concentration of bacteriophages,
cut-off point, is designated with negative degree values. If the
initial bacteriophage titer was 10−1, it may become 10−2 or
10−3 with every dilution round, which indicates that more
active bacteriophage units had been able to kill bacteria and
that the tested bacteria had become less resistant to the adapted
bacteriophages.
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The subsequent titer of the bacteriophages is determined using
two methods: titration in liquid (Appelmans, 1921) and titration
using a double layer agar method (Gratia, 1936). The titration
is done for each component included into Pyo bacteriophages
separately on a standard set of host cultures (i.e., the titer
of the E. coli bacteriophages is determined on the set of the
standard E. coli strains, the titer of Staphylococcus component is
determined on the set of the standard Staphylococcus strains, etc.).
In this way, the titer of the bacteriophages in the range of 107–109
plaque forming units per mL (pfu/mL) is estimated. However, the
titer of the individual (adapted) clones included into one group of
bacteriophages may vary (McCallin et al., 2018).
Microbiological Evaluation and
Bacteriophage Sensitivity Test
In the first phase, urine samples were streaked in triple on
the chromogenic UriselectTM4 media (Bio-Rad Laboratories,
Marnes-la-Coquette, France) for quantification and qualification
of uropathogenic microorganisms. Positive urinary cultures were
microscopically assessed regarding Gram stains and morphology.
For all bacterial strains antibiotic and phage sensitivity tests
were performed. If eligible microorganisms potentially treatable
with Pyo bacteriophage (S. aureus, E. coli, Streptococcus spp.,
P. aeruginosa, P. mirabilis) were found, urine cultures were sent
to the EIBMV and further screened for bacteriophage sensitivity.
Hereto, the urine samples were re-cultivated and their identity
was re-checked. As soon as the same eligible microorganisms
had been cultivated a bacterial cell lysis screening assay was
performed, as described previously (Sybesma et al., 2016).
If in vitro results showed clear confluent lyses on the petri
dish with the bacterial lawn, it was classified as sensitive
(Figure 1). Resistant and intermediate resistant strains were used
in adaptation cycles. In case of sensitivity Pyo bacteriophage
was sent to the hospital to start the treatment. Seven days after
TURP, urine samples were again collected and cultivated in triple
on the above mentioned chromogenic UriselectTM4 media and
re-evaluated.
Intravesical Bacteriophage Treatment
Transurethral resection of prostate was performed according
general surgical practice using a monopolar resectoscope (May
and Hartung, 2006). For low pressure irrigation, a suprapubic
trocar was placed in every patient. No perioperative antibiotic
prophylaxis was given. After TURP a suprapubic catheter and
a transurethral catheter were placed to maintain irrigation.
The transurethral catheter was removed after 24–48 h. The
suprapubic catheter was kept in place for 7 days to enable adapted
Pyo bacteriophage instillation. Pyo bacteriophage was instilled by
a health care provider two times per 24 h (i.e., 8.00 h, 20.00 h) for
7 days, starting the first day after surgery. The solution of 20 mL
was retained in the bladder for approximately 30–60 min.
Assessment of Safety and
Clinical/Microbiological Outcomes
All adverse events within the treatment phase were recorded as
defined by the International Conference on Harmonisation
FIGURE 1 | Different degrees of lyses of bacterial culture due to
bacteriophage activity. The results in upper line (for Pyo bacteriophage and
Intesti bacteriophage) are considered as “S” (sensitive), while the results in the
lower line (Ses bacteriophage and Enko bacteriophage) are considered as “I”
(intermediate). Note: Pyo, Intesti, Ses, and Enko bacteriophage are all
commercially available bacteriophage cocktails. Picture was taken during
previously conducted work (Sybesma et al., 2016) where several different
bacteriophage cocktails were used.
(ICH) Good Clinical Practice (GCP) Guidelines (E6)
(International Conference on Harmonisation, 1996) and
International Organization for Standardization (ISO 14155)
(International Organization for Standardization, 2011). Potential
efficacy was assessed using clinical/microbiological parameters
and defined as no clinical signs for infection and a reduction in
CFU/mL.
Outcome Parameters
Primary: (a) sensitivity of uropathogenic strains to the
commercially available but adapted Pyo bacteriophage (first
phase) and (b) effect of intravesical treatment with adapted Pyo
bacteriophage (second phase).
Secondary: Occurrence/absence of adverse events, in
categorization according to the National Cancer Institute
Common Terminology Criteria for Adverse Events (CTCAE)
version 4 in grade 1 to 51 during bacteriophage treatment (second
phase).
Statistical Analyses
Descriptive statistics were used. Data are presented as percentages
or mean ± standard deviation. Due to the limited number of
subjects no further statistical analyses were performed.
1http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
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RESULTS
First Phase: in vitro Bacteriophage
Sensitivity Testing and Adaptation Cycles
The distribution of bacterial strains of the 118 included patients
is shown in Figure 2. 24% and 17% of all strains were sensitive
and intermediate sensitive to the initially used Pyo bacteriophage
(i.e., total sensitivity of 41%), Figure 3A. After four adaptation
cycles the sensitivity and intermediate sensitivity increased up to
41% and 34% (i.e., total sensitivity 75%), Figure 3B.
Second Phase: Treatment With Adapted
Pyo Bacteriophage
Patients characteristics are found in Table 1. The mean age
was 69 ± 12 years, IPSS questionnaires revealed moderate to
strong LUTS (IPSS 20 ± 2). The average prostate size was
77 ± 37 mL, all PSA values were within the non-pathological
range. Maximum flow rate was 11± 3 mL/s with a mean post void
residual of 80 ± 100 mL. Two patients relied on an indwelling
catheter preoperatively. The average operation time was 48 min,
no complications occurred during prostate surgery. Histological
results revealed benign prostatic hyperplasia in all cases, five
FIGURE 2 | Proportional distribution of bacterial strains. Urinary cultures of
the 118 included patients showed the following distribution of bacterial
strains: E. coli was found predominantly with 41%, followed by Enterococcus
spp. with 29%, Streptococcus spp. with 20%, Pseudomonas aeruginosa with
8%, Staphylococcus spp. 7%, Proteus spp. 4%, and others 9%.
FIGURE 3 | Proportional distribution of the sensitive, intermediate, and
resistant strains among 118 clinical samples before (A) and after (B) four
adaptation cycles of the Pyo bacteriophage cocktail.
patients showed high grade prostatic intraepithelial neoplasia but
no malignant disease was found.
Prior to treatment, urine culture revealed E. coli in four,
Streptococcus spp. in two, Enterococcus spp. in two and
P. aeruginosa in one of the nine patients. After treatment, four
patients showed no significant bacterial growth, while E. coli and
Enterococcus spp. were still isolated from the urine culture of
four and one patient, respectively. In six out of nine patients
(67%), bacterial titers decreased after bacteriophage treatment
(Table 1).
No bacteriophage-associated adverse events have been
detected. In one patient, an antibiotic therapy (third generation
cephalosporin) was started at day 3 after development of fever
(>38.0◦C) and the symptoms disappeared within 48 h. Urine
culture showed P. aeruginosa.
DISCUSSION
In vitro analysis showed a sensitivity for uropathogenic bacteria
to the commercially available Pyo bacteriophage of 41%.
Adaptation cycles of Pyo bacteriophage further enhanced its
sensitivity to 75%. In our in vivo pilot series, the bacterial
titers decreased after bacteriophage treatment in six out of
nine patients (67%). No bacteriophage-associated adverse events
have been detected but one patient developed fever due to
P. aeruginosa infection with restitution of symptoms under
antibiotic treatment.
Our study was designed as a feasibility, tolerability, and safety
assessment and to evaluate clinical/microbiological outcomes of
commercially available adapted Pyo bacteriophages preceding
a placebo-controlled, double-blind RCT (Leitner et al., 2017).
We have not investigated the composition of the continuously
adapted Pyo bacteriophage cocktail by, e.g., metagenome analysis
as recently described for previously used Pyo bacteriophage
cocktails (Villarroel et al., 2017; McCallin et al., 2018), where it
has also been reported that as a result of adaptation the titer of the
individual bacteriophage clones included may vary. We expect
that the detailed elucidation of the composition of bacteriophage
cocktails as well as understanding the mechanisms behind the
bacteriophage infection or bacterial resistance will become more
relevant as soon as more conclusive outcomes about the efficacy
of bacteriophage therapy has been described.
Bacteriophage therapy has already been practiced for decades
in Eastern European countries (Chanishvili, 2012) and many
people are aware of its existence (see also Supplementary
Material for more references, partly in Russian). In the
present open-label pioneering study for a placebo-controlled,
double-blind RCT, the commercially available preparation
Pyo bacteriophage was used for treating nine patients who
were planned for TURP and had been diagnosed with UTI.
Bacteriophage therapy only started after a positive result of an
in vitro sensitivity analysis of the isolated uropathogen with the
Pyo bacteriophage cocktail and did not cause any adverse events
such as rise of body temperature, headache, hematuria, or allergic
reaction in eight out of nine patients. Only in one case (# 9), on
the 3rd day after prostate surgery, fever was observed. After a
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TABLE 1 | Summary of results of intravesical Pyo bacteriophage treatment conducted on nine patients.
Case Age range
(years)
Pre-treatment Post-treatment Prostate
size (g)
PSA value
(µg/L)
Adverse
events/remarks
Culture ID Titer (CFU/mL) Culture ID Titer (CFU/mL)
1 61–65 E. coli 107 E. coli 105 70 1 No adverse events
2 81–85 E. coli 107 E. coli 104 140 2 No adverse events
3 56–60 E. coli 104 E. coli 104 65 0.3 No adverse events
4 81–85 E. coli 107 Non-pathogenic
microflora
Not quantified 90 3.2 No adverse events
5 56–60 Streptococcus 107 Streptococcus 106 130 0.8 No adverse events
6 81–85 Streptococcus 105 No bacterial growth Below detection limit 29 2.3 No adverse events
7 66–70 Enterococcus 106 E. coli 107 45 1 Potential secondary
infection
8 66–70 Enterococcus 106 Non-pathogenic
microflora
Not quantified 60 1.3 No adverse events
9 56–60 Pseudomonas 106 No data No data 60 1.3 Sudden fever and chills
started on the 3rd day
sudden onset of fever (38.5◦C), the bacteriophage treatment was
stopped, while a third generation cephalosporin was prescribed.
In 48 h after the start of antibiotic therapy, the body temperature
was normalized (24 h: 37.8◦C; 48 h: <37.5◦C). In this particular
case the infection was caused by P. aeruginosa, which is known to
release endotoxins during its lysis.
The secondary bacteriology testing of urine samples, taken
after the bacteriophage treatment, demonstrated a positive
tendency in therapy of infection, in particular a decrease of
bacterial counts varying between 1 and 5 logs (cases # 1, 2, 5,
6). In one case (# 6) the secondary bacteriology analysis after
bacteriophage therapy showed that urine had become below
the detection limit of the UriselectTM4 media (104 CFU/mL
for the uropathogens). In two cases (# 4, # 8) the initial
infections, E. coli (titer 107 CFU/mL) and Enterococcus (titer
106 CFU/mL), respectively, had disappeared after bacteriophage
therapy; however, presence of non-pathogenic micro-flora was
observed which did not require any further treatment. It
is notable that in these two cases the non-pathogenic flora
appeared in aged patients 69–80 years old, which may be
a result of urination difficulties remaining even after the
operation. In one case (# 3) the titer of E. coli did not
change after the bacteriophage treatment. In case (# 7) the
initial infection caused by Enterococcus (titer 106 CFU/mL)
after bacteriophage therapy was replaced by E. coli (titer
107 CFU/mL), which may be attributed to a secondary
infection.
Although the design and number of cases and the diversity of
the results described in this publication do not permit to draw out
any statistically reliable conclusions, the trend indicated by the
data from our study does not stand on its own and corresponds
well with the outcome of several other recently reported cases
where bacteriophage therapy was used in Western countries
(Abedon et al., 2017). In terms of safety, the findings of our
prospective two-phase study support earlier made conclusions
that bacteriophage therapy using broad spectrum bacteriophages
cocktails, including Pyo bacteriophage, is safe (McCallin et al.,
2013, 2018; Sarker et al., 2016). However, for a definite conclusion
about efficacy of bacteriophage treatment, well designed RCTs are
urgently needed.
Due to a too high use of antibiotics in today’s society, the
emergence of antibiotic resistance pathogens has become a
serious problem in terms of increased morbidity and mortality
rates as well as the elevated healthcare costs as has been brought to
the public attention by several national and international health
protection agencies (CDC, 2013; European Centre for Disease
et al., 2017; Leitner et al., 2017). Since the resistance mechanism
of bacteria against bacteriophages differs from those against
antibiotics, and since bacteriophage are self-replicating and self-
evolving entities, bacteriophage therapy could be used as an
alternative method to eliminate antibiotic resistant bacteria. One
of the main limitations for acceptance and reimplementation of
bacteriophage therapy is the lack of placebo-controlled, double-
blind RCTs in agreement with Western standards (Expert round
table on acceptance and re-implementation of bacteriophage
therapy, 2016). We expect that the RCT we preceded with the
present open-label study will contribute to conclude on the
efficacy, cost and benefits of bacteriophages in case of antibiotic
resistant uropathogenic bacteria.
Finally, we would like to remark that before bacteriophages
can become accepted and broadly applied for treatment of
certain bacterial infections, as is already practiced in several
Eastern European countries, the legislative framework in the
Western world needs to be adjusted. Since the intrinsic
strength of bacteriophages relates to their antagonistic evolution
potential with their bacterial hosts, the composition of effective
bacteriophages cocktails will not be static, but adapted and
adjusted over time, which assures efficacy toward evolving
bacterial infections at different moments at different places
for different groups of patients. However, such a dynamic
approach is not compatible with today’s production and
admission requirements for chemical drugs. Although the use
of bacteriophages is already quite old, it is remarkable to
acknowledge that in fact a more tailor-made development and
application of bacteriophages are in line with the increasing
needs and opportunities around personalized nutrition and
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personalized medicine. A recent breakthrough in this debate has
been reported for Belgium, where the national authorities agreed
on setting up a practical bacteriophage therapy framework that
relates on the magistral preparation (compounding pharmacy
in the United States) of custom-made bacteriophage medicines
(Pirnay et al., 2018). This Belgian “magistral bacteriophage
medicine” framework is expected to be flexible enough to exploit
and further explore the specific nature of bacteriophages as
co-evolving antibacterials whilst giving precedence to patients’
safety.
CONCLUSION
In our prospective two-phase study preceding a placebo-
controlled, double-blind RCT, adaptation cycles enhanced the
in vitro sensitivity of 118 strains to the commercially available
Pyo bacteriophage from 41% to 75%. In the in vivo pilot
series, a promising clinical and microbiological effect and
excellent tolerability of adapted Pyo bacteriophage treatment
could be shown. Our findings suggest that bacteriophage
therapy might be effective and safe for treating UTIs.
Thus, well-designed RCTs are highly warranted to further
define the role of this potentially revolutionizing treatment
option.
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